Oncolytics Biotech (ONCY) to Release Quarterly Earnings on Thursday

Oncolytics Biotech (NASDAQ:ONCY) is set to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Oncolytics Biotech (NASDAQ:ONCY) last released its earnings results on Thursday, March 7th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncolytics Biotech Stock Up 0.8 %

Oncolytics Biotech stock opened at $1.19 on Wednesday. The stock has a 50-day moving average price of $1.07 and a 200 day moving average price of $1.24. The company has a market capitalization of $89.75 million, a price-to-earnings ratio of -3.97 and a beta of 1.91. Oncolytics Biotech has a 52 week low of $0.88 and a 52 week high of $3.39.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ONCY shares. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Wednesday, February 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oncolytics Biotech in a research report on Friday, January 12th. Finally, Raymond James assumed coverage on Oncolytics Biotech in a research report on Thursday, April 4th. They set an “outperform” rating and a $3.00 price target for the company.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.